AirFit N20 Cushion Replacement: Designed for the ResMed AirFit N20 nasal CPAP mask, this cushion supports optimal sleep apnea therapy Comfort Plus CPAP Mask Cushion: Crafted from soft silicone ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

But hidden at your pharmacy among the potpourri of cough drops and cold remedies, you can find a low-risk treatment that actually may help: nasal irrigation devices. Several small studies suggest ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

Optima Aero moves inventory to avoid potential US tariffs Aerospace industry fears disruption from tariffs Canada threatens retaliatory tariffs if targeted by Trump MONTREAL, Jan 24 (Reuters ...

A nasal rinse is a common practice to clear nasal passages, especially during cold, flu, and allergy seasons. It helps remove mucus, debris, and allergens that build in the nose. “A saltwater rinse is ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...